Is Gossamer Bio, Inc. (GOSS) a Buy, Sell, or Hold?
NASDAQ : GOSS
Gossamer Bio, Inc.
$0.2099 USD
$0.01 (5.27%)
- Volume
- 147.87M
- Average Volume
- 15.11M
- Market Capitalization
- $49.23M
- P/E Ratio
- -0.27
- Dividend Yield
- 0.00%
- Price Target
- $1.00
- Year High
- $3.87
- Year Low
- $0.11
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $2.20
Company Overview
NASDAQ
Faheem Hasnain
Biotechnology
Healthcare
GOSS
162
US
USD
Liquidity Metrics
-1.26
2.20
2.20
0.73
0.00
Sales & Valuation
$48.47M
0.89
-0.30
-0.29
-0.73
Profitability
-$0.75
-$170.37M
-324.82%
-324.98%
174.85%
-139.95%
P/E Metrics
-0.27
0.00
0.00
Analyst Price Target & Rating
$1.00
$1.00
$0.30
2/5
17 Analysts
-79.01%
Financial Health Scores
-19.34
1/9
$68.03M
$128.9M
$290.38M
-$169.49M
Key Metrics (TTM)
$208.67M
3.76
-1.24
2.20
174.85%
-243.62%
-386.39%
-364.16%
-16965 days
Company Executives
| Name | Title |
|---|---|
| Richard Aranda | Chief Medical Officer |
| Kelly Dawson | Senior Vice President of Program Team Lead |
| Bryan Giraudo | Chief Operating Officer & Chief Financial Officer |
| Christian Waage | Executive VP, General Counsel & Secretary |
| Robert Smith | Chief Commercial Officer |
| Caryn L. Peterson | Chief Development Officer |
| Faheem Hasnain | Co-Founder, Chief Executive Officer, President & Chairman |
| Jeanine Anthony | Senior Vice President of Marketing |
| Matt Cravets | Senior Vice President of Biometrics |
| Deanna Weber | Executive Vice President of Human Resources |
| Robert F. Roscigno | Senior Vice President of Clinical Development of Pulmonary Vascular Disease |
| Conor O'Donovan | Senior Vice President of Regulatory Affairs |
| Louis K. Cherico | Senior Vice President of Finance & Treasury |
Poll Results
No votes yet today — be the first to share your view!
About Gossamer Bio, Inc. (NASDAQ:GOSS) Stock
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary hypertension and pulmonary arterial hypertension in the United States. The company develops GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. The company was incorporated in 2015 and is headquartered in San Diego, California. ...
Gossamer Bio Restructures Debt, Secures Full Control of Lead Drug Candidate
2026-07-27 14:11:20
Gossamer Bio Inc. (NASDAQ:GOSS) stock is trading higher on Monday as the company is preparing to submit a New Drug Application (NDA) for its lead candidate, seralutinib, in September 2026 following a pre-NDA Type B meeting with the U.S. Food and Drug Administration (FDA).
2026-07-27 12:38:49
Gossamer Bio, Inc. (GOSS) Discusses Reacquisition of Seralutinib Rights, Regulatory Progress and Capital Structure Updates Transcript
2026-07-27 07:00:00
SAN DIEGO--(BUSINESS WIRE)---- $GOSS--Gossamer Bio, Inc. (Nasdaq: GOSS) (the “Company” or “Gossamer”), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), announced a series of regulatory, strategic, and corporate updates. Following a productive Pre-NDA Type B meeting with the U.S. Food and Drug Administration (FDA).
2026-07-01 09:00:00
SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (NASDAQ: GOSS) (the “Company” or “Gossamer”), a biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that the initial conversion rate for its 7.50% Convertible Senior Secured First Lien Notes due 2030 (the “2030 Convertible Notes”) will be 5,347.5936 shares of t.
2026-06-17 08:00:00
SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (NASDAQ: GOSS) (the “Company” or “Gossamer”), a biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced the final tender results of its previously announced exchange offer (the “Exchange Offer”) to exchange any and all of its 5.00% Convertible Senior Notes due 202.
2026-06-03 08:00:00
SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (NASDAQ: GOSS) (the “Company” or “Gossamer”), a biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced the early tender results of its previously announced exchange offer (the “Exchange Offer”) to exchange any and all of its 5.00% Convertible Senior Notes due 202.
2026-06-02 08:00:00
SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (NASDAQ: GOSS) (the “Company” or “Gossamer”), a biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that it has extended the early tender date (as extended, the “Extended Early Tender Date”) until 5:00 p.m., New York City time, on June 2, 2026 with respect to.
2026-06-01 13:00:00
[url="]Faruqi and Faruqi, LLP[/url], a leading national securities law firm, is investigating potential claims against Gossamer Bio, Inc. (âGossamerâ or the â
Frequently Asked Questions
-
What is the current Gossamer Bio, Inc. (GOSS) stock price?
-
Gossamer Bio, Inc.(NASDAQ:GOSS) stock price is $0.2099 in the last trading session. During the trading session, GOSS stock reached the peak price of $3.87 while $0.114 was the lowest point it dropped to. The percentage change in GOSS stock occurred in the recent session was 5.27% while the dollar amount for the price change in GOSS stock was $0.01.
-
GOSS's industry and sector of operation?
-
The NASDAQ listed GOSS is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of GOSS?
-
Richard Aranda | Chief Medical Officer
Kelly Dawson | Senior Vice President of Program Team Lead
Bryan Giraudo | Chief Operating Officer & Chief Financial Officer
Christian Waage | Executive VP, General Counsel & Secretary
Robert Smith | Chief Commercial Officer -
How many employees does GOSS have?
-
Number of GOSS employees currently stands at 162. GOSS operates from 3115 Merryfield Row, San Diego, CA 92121, US.
-
Link for GOSS official website?
-
Official Website of GOSS is: https://www.gossamerbio.com
-
How do I contact GOSS?
-
GOSS could be contacted at phone #858 684 1300 and can also be accessed through its website. GOSS operates from 3115 Merryfield Row, San Diego, CA 92121, US.
-
How many shares of GOSS are traded daily?
-
The average number of GOSS shares traded daily for last 3 months was 15.11M.
-
What is the market cap of GOSS currently?
-
The market value of GOSS currently stands at $49.23M with its latest stock price at $0.2099